D-Allulose Alleviates High-Fat Diet-Induced NAFLD in Mice by Reducing Lipid Accumulation and Inflammation

Formulators, here is a reason to look at allulose beyond its sugar-like taste. A 2025 study in Frontiers in Nutrition tested D-allulose in a mouse model of non-alcoholic fatty liver disease (NAFLD). The results point to real metabolic benefits. D-allulose delivers only 0.3% of sucrose’s energy, but the study found it also reduces fat buildup in the liver and calms inflammation. That makes it more than a bulking sweetener. It may become a functional ingredient for metabolic health.

Background: why NAFLD matters to food formulators

NAFLD now affects a large share of adults worldwide. Excess fructose and sucrose drive fat production in the liver. Fat accumulates. Then inflammation follows. Food brands looking for sugar reduction need ingredients that don’t just replace sweetness. They need ingredients that don’t add to the problem. D-allulose, a rare sugar, has a unique profile: it tastes like sucrose, bakes like sugar, and has almost no calories. This study asked whether it can also protect the liver.

What the study did

Researchers fed mice a high-fat diet to induce NAFLD. One group received D-allulose alongside the diet. The team then measured liver lipid content, inflammatory markers, serum lipids, oxidative stress, gut microbiota, and serum metabolites. They compared these outcomes against the control group on the high-fat diet without D-allulose.

The study did not just look at weight. It looked at the liver itself. Histology and biochemical assays tracked how much fat accumulated in hepatic tissue. The researchers also sequenced gut bacteria and ran metabolomic analysis. That gave a whole-body view, linking the liver to the gut.

Key findings

D-allulose reduced liver lipid accumulation. It also lessened inflammatory injury. Mice receiving D-allulose showed better serum lipid profiles and lower oxidative stress. These effects came through two broad mechanisms: inhibition of lipid synthesis and anti-inflammatory activity.

The gut microbiota shifted as well. D-allulose increased beneficial bacteria, including Akkermansia. That genus has strong links to gut barrier health and metabolic regulation. Serum metabolome balance also recovered. In other words, D-allulose changed more than a single liver enzyme. It reshaped the gut-liver axis.

Measurement	Effect seen with D-allulose
Liver lipids	Reduced accumulation
Inflammatory injury	Reduced
Serum lipids	Improved profile
Oxidative stress	Lowered
Gut microbiota	Increased beneficial bacteria (Akkermansia)
Serum metabolome	Restored balance
Energy from sucrose	Only 0.3%

What it means for manufacturers

You can formulate with allulose today for clean-label sweetness. This study adds another angle. If human data confirms these findings, allulose could support claims around liver health or metabolic wellness. That would be a strong position for products targeting weight management, low-sugar baking, or functional beverages.

But be careful with dosage. The study used a mouse model. Human equivalent doses are not established from this paper alone. You need to check the actual allulose content per serving and keep claims within regulatory boundaries. Also, allulose is not digested like sucrose. It still participates in Maillard browning, so you can use it in baked goods with reduced sugar. The metabolic benefits, if they translate, would come as a bonus.

Think about pairing allulose with prebiotic fibers. The gut microbiota shift toward Akkermansia suggests synergy with fiber-rich formulations. A low-sugar bar with allulose and inulin might support both sweetness and microbial health. The science is young, but the direction is clear.

FAQ

Is D-allulose the same as D-psicose? Yes. D-allulose is the international name for D-psicose. The paper uses DPS as the abbreviation. It is a low-calorie rare sugar found in small quantities in wheat, figs, and raisins.

Did the study test humans? No. This was a mouse study. The authors examined high-fat diet-induced NAFLD in mice. Human trials remain necessary before making health claims.

Can allulose replace sucrose one-to-one in formulations? Often yes. Allulose provides about 70% of sucrose’s sweetness and similar bulk. It also caramelizes and browns like sugar. You may need to adjust sweetener levels or combine with high-intensity sweeteners, but its physical behavior matches sugar closely in most bakery applications.

This paper gives food formulators a new reason to take allulose seriously. It already solves classic sugar-reduction problems. Now it shows potential to reduce liver fat, fight inflammation, and improve gut ecology in a disease model. That combination is rare. Keep watching for human data, and start testing allulose in your prototypes now. The next generation of metabolic health products may hinge on this small sweet molecule.